143 related articles for article (PubMed ID: 37721774)
1. Efficacy, tolerability and patient's satisfaction for the treatment of moderate to severe plaque psoriasis with apremilast in the real-life setting of Campania region, Italy.
Licata G; Tancredi V; Gambardella A; Megna M; Fabbrocini G; Raimondo A; Lembo S; Ligrone L; Cusano F; Argenziano G
Ital J Dermatol Venerol; 2023 Dec; 158(6):452-456. PubMed ID: 37721774
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
4. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
[TBL] [Abstract][Full Text] [Related]
6. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
Giofrè C; Fabbrocini G; Potenza C; Tiberio R; Gisondi P; Marasca C; Nuzzo CMA; Benincasa E; Bianchi L;
Adv Ther; 2023 Jul; 40(7):3021-3037. PubMed ID: 37171752
[TBL] [Abstract][Full Text] [Related]
7. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
10. Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe.
Cetkovská P; Dediol I; Šola M; Kojanová M; Trčko K; Čarija A; Čeović R; Ledić-Drvar D; Kaštelan M; Hrabar A; Missoup MC; Mamun K
Adv Ther; 2023 Apr; 40(4):1787-1802. PubMed ID: 36862361
[TBL] [Abstract][Full Text] [Related]
11. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; Suárez-Pérez JA; Armesto S; Rivera R; Herrera-Acosta E; Herranz P; Martín I; Montesinos E; Hospital M; Vilarrasa E; Ferran M; Ruiz-Villaverde R; Sahuquillo-Torralba A; Ruiz-Genao DP; Pérez-Barrio S; Muñoz C; Llamas M; Valentí F; Mitxelena MJ; López-Ferrer A; Carretero G; Vidal D; Mollet J; Belinchón I; Carrascosa JM
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2821-2829. PubMed ID: 32271966
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
Ghislain PD; Lambert J; Lam Hoai XL; Hillary T; Roquet-Gravy PP; de la Brassinne M; Segaert S
Adv Ther; 2022 Feb; 39(2):1068-1080. PubMed ID: 34977985
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
[TBL] [Abstract][Full Text] [Related]
15. Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.
van den Reek JMPA; van der Leest RJT; Thomas SE; Prevoo R; Plantenga ME; de Jong EMGJ
Adv Ther; 2024 Apr; 41(4):1594-1605. PubMed ID: 38402373
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
18. A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study.
Ioannides D; Antonakopoulos N; Chasapi V; Oikonomou C; Tampouratzi E; Lazaridou E; Rigopoulos D; Neofotistou O; Drosos A; Anastasiadis G; Rovithi E; Kalinou C; Papadavid E; Aronis P; Papageorgiou M; Protopapa A; Bassukas I; Lefaki I; Zafiriou E; Krasagakis K; Pokas E; Anagnostopoulos Z; Kekki A; Papakonstantis M
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2055-2063. PubMed ID: 35451115
[TBL] [Abstract][Full Text] [Related]
19. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy.
Galluzzo M; Caldarola G; De Simone C; Bernardini N; Moretta G; Pallotta S; Botti E; Campione E; Pirro F; Potenza C; Bianchi L; Peris K
Expert Opin Biol Ther; 2021 Sep; 21(9):1299-1310. PubMed ID: 34114515
[No Abstract] [Full Text] [Related]
20. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.
Reich K; Mrowietz U; Menter A; Griffiths CEM; Bagel J; Strober B; Nunez Gomez N; Shi R; Guerette B; Lebwohl M
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2409-2414. PubMed ID: 34255891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
